Welcome to AdisInsight

Please enter your official email address

Email Address
Please enter your official email address

Your email address will be used to create a unique number used exclusively to identify you on AdisInsight. Your email address will not be stored or maintained within AdisInsight. Your unique identifier number will be stored in your browser data on your device. This will allow us to know it’s you when you access AdisInsight from your computer, tablet, or phone. To do this you will need to enter your email address the first time to visit AdisInsight from a new device. After that we will recognize you and you will not have to enter your email again unless you have deleted your browser data. We will use your unique identifier number to provide anonymous information to your subscribing organization to allow them to accurately assess the value AdisInsight delivers. For additional information on how we protect your personal information, please refer to our
privacy policy
.

A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease

At a glance

Most Recent Events

01 Aug 2018
According to a Biohaven Pharmaceutical media release, if the results are positive from this study, the company may contribute to the regulatory package necessary to establish the effectiveness of trigriluzole for the treatment of Alzheimer's disease. The first patients has been enrolled in this study.

24 Jul 2018
According to a Biohaven Pharmaceutical Holding Company media release, The initiation of this trial follows Biohavens filing of an investigational new drug application (IND) for trigriluzole in AD and receipt from FDA of authorization to proceed with clinical investigation in this indication.

24 Jul 2018
According to a Biohaven Pharmaceutical Holding Company media release, Status changed from planning to recruiting.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription